Literature DB >> 15619617

Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy.

Dong-Ho Kim, Mark A Behlke, Scott D Rose, Mi-Sook Chang, Sangdun Choi, John J Rossi.   

Abstract

RNA interference (RNAi) is the process of sequence-specific post-transcriptional gene silencing triggered by double-stranded RNAs. In attempts to identify RNAi triggers that effectively function at lower concentrations, we found that synthetic RNA duplexes 25-30 nucleotides in length can be up to 100-fold more potent than corresponding conventional 21-mer small interfering RNAs (siRNAs). Some sites that are refractory to silencing by 21-mer siRNAs can be effectively targeted by 27-mer duplexes, with silencing lasting up to 10 d. Notably, the 27-mers do not induce interferon or activate protein kinase R (PKR). The enhanced potency of the longer duplexes is attributed to the fact that they are substrates of the Dicer endonuclease, directly linking the production of siRNAs to incorporation in the RNA-induced silencing complex. These results provide an alternative strategy for eliciting RNAi-mediated target cleavage using low concentrations of synthetic RNA as substrates for cellular Dicer-mediated cleavage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15619617     DOI: 10.1038/nbt1051

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  300 in total

1.  Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs.

Authors:  Pinal C Patel; Liangliang Hao; Weng Si Au Yeung; Chad A Mirkin
Journal:  Mol Pharm       Date:  2011-06-28       Impact factor: 4.939

2.  Dicer-substrate siRNA inhibits tumor necrosis factor alpha secretion in Kupffer cells in vitro: in vivo targeting of Kupffer cells by siRNA-liposomes.

Authors:  Sivakamasundari Pichu; Swapna Krishnamoorthy; Bi Zhang; Yawu Jing; Andrei Shishkov; Biddanda C Ponnappa
Journal:  Pharmacol Res       Date:  2011-09-10       Impact factor: 7.658

3.  Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo.

Authors:  Donald J Foster; Scott Barros; Rick Duncan; Sarfraz Shaikh; William Cantley; Amy Dell; Elena Bulgakova; Jonathan O'Shea; Nate Taneja; Satya Kuchimanchi; Christopher B Sherrill; Akin Akinc; Gregory Hinkle; Amy C Seila White; Bo Pang; Klaus Charisse; Rachel Meyers; Muthiah Manoharan; Sayda M Elbashir
Journal:  RNA       Date:  2012-01-31       Impact factor: 4.942

Review 4.  RNA-based therapeutics: current progress and future prospects.

Authors:  John C Burnett; John J Rossi
Journal:  Chem Biol       Date:  2012-01-27

5.  RNAimmuno: a database of the nonspecific immunological effects of RNA interference and microRNA reagents.

Authors:  Marta Olejniczak; Paulina Galka-Marciniak; Katarzyna Polak; Andrzej Fligier; Wlodzimierz J Krzyzosiak
Journal:  RNA       Date:  2012-03-12       Impact factor: 4.942

Review 6.  RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.

Authors:  Nicholas M Snead; John J Rossi
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

7.  Reduced seed region-based off-target activity with lentivirus-mediated RNAi.

Authors:  Richard A Klinghoffer; Jill Magnus; Janell Schelter; Michele Mehaffey; Casey Coleman; Michele A Cleary
Journal:  RNA       Date:  2010-03-26       Impact factor: 4.942

8.  Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer.

Authors:  Juan R Cubillos-Ruiz; Jason R Baird; Amelia J Tesone; Melanie R Rutkowski; Uciane K Scarlett; Ana L Camposeco-Jacobs; Jorge Anadon-Arnillas; Noah M Harwood; Murray Korc; Steven N Fiering; Lorenzo F Sempere; Jose R Conejo-Garcia
Journal:  Cancer Res       Date:  2012-02-03       Impact factor: 12.701

9.  Prostate-targeted mTOR-shRNA inhibit prostate cancer cell growth in human tumor xenografts.

Authors:  Yue-Feng Du; Qing-Zhi Long; Ying Shi; Xiao-Gang Liu; Xu-Dong Li; Jin Zeng; Yong-Guang Gong; Xin-Yang Wang; Da-Lin He
Journal:  Int J Clin Exp Med       Date:  2013-01-26

Review 10.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.